XASEMTNB
Market cap112mUSD
Dec 23, Last price
0.52USD
1D
-4.57%
1Q
-85.47%
Jan 2017
-99.26%
IPO
-99.20%
Name
Matinas BioPharma Holdings Inc
Chart & Performance
Profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,096 -65.62% | 3,188 9,464.10% | 33 -78.95% | |||||||
Cost of revenue | 39,351 | 44,456 | 25,550 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (38,255) | (41,268) | (25,516) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (7,982) | (2,110) | ||||||||
Tax Rate | ||||||||||
NOPAT | (38,255) | (33,286) | (23,406) | |||||||
Net income | (22,942) 76.27% | (13,015) -38.53% | (21,173) 2.79% | |||||||
Dividends | (843,600) | |||||||||
Dividend yield | 7.95% | |||||||||
Proceeds from repurchase of equity | 99 | 6,996 | ||||||||
BB yield | 0.00% | -0.07% | ||||||||
Debt | ||||||||||
Debt current | 1,322 | 569 | 560 | |||||||
Long-term debt | 6,451 | 7,679 | 8,846 | |||||||
Deferred revenue | (341) | (341) | ||||||||
Other long-term liabilities | 341 | 341 | ||||||||
Net debt | (5,983) | (20,715) | (40,217) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (15,278) | (19,156) | (15,223) | |||||||
CAPEX | (218) | (892) | (260) | |||||||
Cash from investing activities | 13,242 | 4,877 | 16,770 | |||||||
Cash from financing activities | (7) | 79 | 6,965 | |||||||
FCF | (36,014) | 1,332,434 | 1,480,642 | |||||||
Balance | ||||||||||
Cash | 13,756 | 28,763 | 49,622 | |||||||
Long term investments | 200 | |||||||||
Excess cash | 13,701 | 28,804 | 49,620 | |||||||
Stockholders' equity | (175,772) | (153,433) | (131,758) | |||||||
Invested Capital | 199,235 | 194,194 | 188,954 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 4,345 | 216,811 | 210,178 | |||||||
Price | 10.81 -56.76% | 25.00 -50.50% | 50.50 -25.74% | |||||||
Market cap | 46,973 -99.13% | 5,420,286 -48.93% | 10,614,006 -20.72% | |||||||
EV | 40,990 | 5,399,571 | 10,573,789 | |||||||
EBITDA | (37,314) | (40,370) | (24,735) | |||||||
EV/EBITDA | ||||||||||
Interest | 3,593 | |||||||||
Interest/NOPBT |